SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-498008"
 

Search: onr:"swepub:oai:DiVA.org:uu-498008" > Finerenone in Patie...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Rossing, Peter (author)

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment : The FIDELITY Analysis.

  • Article/chapterEnglish2022

Publisher, publication year, extent ...

  • 2022-08-15
  • American Diabetes Association,2022
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-498008
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-498008URI
  • https://doi.org/10.2337/dc22-0294DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • OBJECTIVE: Finerenone reduced the risk of kidney and cardiovascular events in people with chronic kidney disease (CKD) and type 2 diabetes in the FIDELIO-DKD and FIGARO-DKD phase 3 studies. Effects of finerenone on outcomes in patients taking sodium-glucose cotransporter 2 inhibitors (SGLT2is) were evaluated in a prespecified pooled analysis of these studies.RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes and urine albumin-to-creatinine ratio (UACR) ≥30 to ≤5,000 mg/g and estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73 m2 were randomly assigned to finerenone or placebo; SGLT2is were permitted at any time. Outcomes included cardiovascular composite (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) and kidney composite (kidney failure, sustained ≥57% eGFR decline, or renal death) end points, changes in UACR and eGFR, and safety outcomes.RESULTS: Among 13,026 patients, 877 (6.7%) received an SGLT2i at baseline and 1,113 (8.5%) initiated one during the trial. For the cardiovascular composite, the hazard ratios (HRs) were 0.87 (95% CI 0.79-0.96) without SGLT2i and 0.67 (95% CI 0.42-1.07) with SGLT2i. For the kidney composite, the HRs were 0.80 (95% CI 0.69-0.92) without SGLT2i and 0.42 (95% CI 0.16-1.08) with SGLT2i. Baseline SGLT2i use did not affect risk reduction for the cardiovascular or kidney composites with finerenone (Pinteraction = 0.46 and 0.29, respectively); neither did SGLT2i use concomitant with study treatment.CONCLUSIONS: Benefits of finerenone compared with placebo on cardiorenal outcomes in patients with CKD and type 2 diabetes were observed irrespective of SGLT2i use.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Anker, Stefan D (author)
  • Filippatos, Gerasimos (author)
  • Pitt, Bertram (author)
  • Ruilope, Luis M (author)
  • Birkenfeld, Andreas L (author)
  • McGill, Janet B (author)
  • Rosas, Sylvia E (author)
  • Joseph, Amer (author)
  • Gebel, Martin (author)
  • Roberts, Luke (author)
  • Scheerer, Markus F (author)
  • Bakris, George L (author)
  • Agarwal, Rajiv (author)

Related titles

  • In:Diabetes Care: American Diabetes Association45:12, s. 2991-29980149-59921935-5548

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view